Skip to main content
Premium Trial:

Request an Annual Quote

With A Nasty Note from Nasdaq for Cytogen, AxCell Could Be Up for Sale

NEW YORK, Aug. 15 - The 90-day Nasdaq delisting countdown started yesterday for Cytogen, a move that could put additional pressure on the company to divest itself of proteomics subsidiary AxCell Biosciences.


After 30 consecutive trading days of rock-bottom stock prices, Cytogen received official notice from the exchange yesterday that it must find a way to boost its performance or risk being delisted.


By Nasdaq rules, if a company's stock closes below the $1 minimum for more than 30 consecutive trading days it is given 90 days to shape up or face getting booted off the exchange. If the company manages to bring its share price above that low water mark during that period for at least 10 consecutive trading days it's off the hook.


Cytogen shares last traded over $1 on July 11, and the stock has not closed above $1 since July 1. The company has until Nov. 12 to comply with Nasdaq requirements.


At the end of May, Cytogen said it was "reviewing strategic alternatives" for AxCell, which consumes a healthy portion of the company's roughly $11 million annual R&D budget.


Cytogen, based in Princeton, NJ, develops oncology drugs and prostate cancer treatments. AxCell markets a signal transduction pathway database for clinical research and functional proteomics.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more